In the Unicancer Epidemiological Strategy and Medical Economics (ESME) MBC database (n = 16,701), 24.6% of the patients developed BM and the risk was higher for patients with HER2-positive/hormone receptor (HR)-negative and triple-negative (TNBC) breast cancer [2]. This evidence concerns the gene ERBB2 and breast carcinoma.